NCT06894511
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06894511
Title An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (PSMAndARPI)
Acronym PSMAndARPI
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Cancer And Blood Spclsts of AZ Casa Grande Arizona 85122 United States Details
Arizona Center for Cancer Care Gilbert Arizona 85297 United States Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Hoag Memorial Hospital Presbyterian Newport Beach California 92663 United States Details
Univ Of Color Anschutz Med Center Aurora Colorado 80045 United States Details
Cancer Specialists of North Florida Jacksonville Florida 32256 United States Details
East Jefferson Hospital Metairie Louisiana 70006 United States Details
Urology Cancer Center PC Omaha Nebraska 68130 United States Details
Northwest Cancer Specialists Portland Oregon 97210 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
Texas Oncology P A Bedford Texas 76022 United States Details
Urology Austin Lakeway Texas 78738 United States Details
Urology San Antonio San Antonio Texas 78229 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field